Ravinder K. Grewal - Concepedia

Author

Ravinder K. Grewal

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Grewal, R., Grewal, Ravinder Kaur, R. Grewal, R. K. Grewal, R.K. Grewal, Ravinder Grewal, Ravinder K Grewal, Ravinder K. Grewal, Ravinder Kaur Grewal, Razik GREWAL

168

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Tel Aviv University University of Saskatchewan University of Michigan

About

Ravinder K. Grewal is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, radiology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	12	523
2	Health Sciences	8	8	452
3	Engineering	3	3	224
4	Natural Sciences	1	1	91
5	Public Health	1	1	21

Ravinder K. Grewal

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer Alan L. Ho, Ravinder K. Grewal, Rébecca Leboeuf, New England Journal of Medicine	2013	810
Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning Richard J. Robbins, Qiang Wan, Ravinder K. Grewal, The Journal of Clinical Endocrinology & Metabolism	2006	581
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. Henry Yeung, Ravinder K. Grewal, Mithat Gönen, PubMed	2003	377
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom, The Lancet Oncology Lymphoid NeoplasiaRefractory HodgkinAugmented IfosamideBrentuximab VedotinMedicine	2015	263
Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers Lara Dunn, Eric J. Sherman, Shrujal S. Baxi, The Journal of Clinical Endocrinology & Metabolism	2018	231
Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation Ravinder K. Grewal, Steven M. Larson, Christina E. Pentlow, Journal of Nuclear Medicine	2009	143
Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal R. Michael Tuttle, Matvey Brokhin, Gal Omry, Journal of Nuclear Medicine	2008	140
Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases Mona M. Sabra, José Miguel Domínguez, Ravinder K. Grewal, The Journal of Clinical Endocrinology & Metabolism	2013	133
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma Alison J. Moskowitz, Heiko Schöder, Somali Gavane, Blood	2017	133
In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response Fernanda Vaisman, Hernán Tala, Ravinder K. Grewal, Thyroid	2011	131

Page 1